vs
Amarin Corp plc（AMRN）与UNIVERSAL HEALTH REALTY INCOME TRUST（UHT）财务数据对比。点击上方公司名可切换其他公司
Amarin Corp plc的季度营收约是UNIVERSAL HEALTH REALTY INCOME TRUST的1.8倍（$45.1M vs $24.5M），UNIVERSAL HEALTH REALTY INCOME TRUST净利率更高（17.7% vs -23.3%，领先41.0%），Amarin Corp plc同比增速更快（7.0% vs -0.7%），过去两年UNIVERSAL HEALTH REALTY INCOME TRUST的营收复合增速更高（-1.3% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
环球健康服务公司（UHS）是一家总部位于宾夕法尼亚州普鲁士国王市的美国医疗服务企业，位列财富500强，主营医院运营及各类医疗保健服务。该公司2024年公布的总营收达158亿美元。
AMRN vs UHT — 直观对比
营收规模更大
AMRN
是对方的1.8倍
$24.5M
营收增速更快
AMRN
高出7.7%
-0.7%
净利率更高
UHT
高出41.0%
-23.3%
两年增速更快
UHT
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $24.5M |
| 净利润 | $-10.5M | $4.3M |
| 毛利率 | — | — |
| 营业利润率 | 35.5% | 34.7% |
| 净利率 | -23.3% | 17.7% |
| 营收同比 | 7.0% | -0.7% |
| 净利润同比 | 33.0% | -7.2% |
| 每股收益（稀释后） | — | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNUHT
| Q1 26 | $45.1M | — | ||
| Q4 25 | $49.2M | $24.5M | ||
| Q3 25 | $49.7M | $25.3M | ||
| Q2 25 | $72.7M | $24.9M | ||
| Q1 25 | $42.0M | $24.5M | ||
| Q4 24 | $62.3M | $24.6M | ||
| Q3 24 | $42.3M | $24.5M | ||
| Q2 24 | $67.5M | $24.7M |
净利润AMRNUHT
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | $4.3M | ||
| Q3 25 | $-7.7M | $4.0M | ||
| Q2 25 | $-14.1M | $4.5M | ||
| Q1 25 | $-15.7M | $4.8M | ||
| Q4 24 | $-48.6M | $4.7M | ||
| Q3 24 | $-25.1M | $4.0M | ||
| Q2 24 | $1.5M | $5.3M |
毛利率AMRNUHT
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
营业利润率AMRNUHT
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | 34.7% | ||
| Q3 25 | -22.4% | 33.2% | ||
| Q2 25 | -22.0% | 35.6% | ||
| Q1 25 | -39.9% | 36.8% | ||
| Q4 24 | -84.3% | 37.6% | ||
| Q3 24 | -59.5% | 34.7% | ||
| Q2 24 | -0.8% | 38.7% |
净利率AMRNUHT
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | 17.7% | ||
| Q3 25 | -15.6% | 15.9% | ||
| Q2 25 | -19.4% | 18.1% | ||
| Q1 25 | -37.4% | 19.5% | ||
| Q4 24 | -78.0% | 18.9% | ||
| Q3 24 | -59.4% | 16.3% | ||
| Q2 24 | 2.3% | 21.3% |
每股收益（稀释后）AMRNUHT
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | $0.32 | ||
| Q3 25 | $-0.02 | $0.29 | ||
| Q2 25 | $-0.03 | $0.32 | ||
| Q1 25 | $-0.04 | $0.34 | ||
| Q4 24 | $-0.12 | $0.34 | ||
| Q3 24 | $-0.06 | $0.29 | ||
| Q2 24 | $0.00 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | $6.7M |
| 总债务越低越好 | — | $374.8M |
| 股东权益账面价值 | — | $152.4M |
| 总资产 | $645.8M | $564.9M |
| 负债/权益比越低杠杆越低 | — | 2.46× |
8季度趋势，按日历期对齐
现金及短期投资AMRNUHT
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | $6.7M | ||
| Q3 25 | $286.6M | $6.9M | ||
| Q2 25 | $298.7M | $6.6M | ||
| Q1 25 | $281.8M | $7.0M | ||
| Q4 24 | $294.2M | $7.1M | ||
| Q3 24 | $305.7M | $6.4M | ||
| Q2 24 | $306.7M | $5.6M |
总债务AMRNUHT
| Q1 26 | — | — | ||
| Q4 25 | — | $374.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $368.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益AMRNUHT
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | $152.4M | ||
| Q3 25 | $458.9M | $158.6M | ||
| Q2 25 | $464.9M | $165.2M | ||
| Q1 25 | $473.7M | $172.2M | ||
| Q4 24 | $486.2M | $179.5M | ||
| Q3 24 | $531.4M | $181.6M | ||
| Q2 24 | $551.9M | $190.7M |
总资产AMRNUHT
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | $564.9M | ||
| Q3 25 | $659.8M | $568.0M | ||
| Q2 25 | $670.1M | $573.0M | ||
| Q1 25 | $655.7M | $573.5M | ||
| Q4 24 | $685.3M | $580.9M | ||
| Q3 24 | $750.6M | $584.3M | ||
| Q2 24 | $799.9M | $586.6M |
负债/权益比AMRNUHT
| Q1 26 | — | — | ||
| Q4 25 | — | 2.46× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $49.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 11.35× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRNUHT
| Q1 26 | — | — | ||
| Q4 25 | $15.3M | $49.1M | ||
| Q3 25 | $-12.7M | $10.2M | ||
| Q2 25 | $16.6M | $13.7M | ||
| Q1 25 | $-12.5M | $11.6M | ||
| Q4 24 | $-13.3M | $46.9M | ||
| Q3 24 | $-2.4M | $9.9M | ||
| Q2 24 | $-2.7M | $12.1M |
现金转化率AMRNUHT
| Q1 26 | — | — | ||
| Q4 25 | — | 11.35× | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | 3.05× | ||
| Q1 25 | — | 2.43× | ||
| Q4 24 | — | 10.06× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | -1.81× | 2.30× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
UHT
| Reportable Segment Aggregation Before Other Operating Segment | $23.1M | 94% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $2.3M | 9% |
